Atrophic Gastritis, Gastric Cancer, Intestinal Metaplasia
Conditions
Keywords
Gastric cancer, Gastroscopy, Atrophic gastritis, Intestinal metaplasia
Brief summary
This is a multi-center prospective case control study aiming to compare different methods of risk stratification models in predicting the risk of gastric cancer development.
Detailed description
The case control study would compare which type of assessment (Endoscopic / histological) is more accurate in predicting the risk of gastric cancer development. The risk factor assessment would be based on the following criteria. Endoscopic assessment: 1. Atrophic gastritis, based on Kimura Takemoto Classification 2. Kyoto classification of gastritis 3. Intestinal metaplasia, based on Endoscopic Mapping and Grading of Intestinal Metaplasia (EGGIM) Histological assessment (Based on random biopsies) 1\. Operative Links on Gastritis Assessment 2. Operative Links on Gastric Intestinal Metaplasia
Interventions
DIAGNOSTIC_TESTGastroscopy and gastric biopsies
Gastroscopy would be performed to assess the degree of atrophic gastritis and intestinal metaplasia. In addition, four random biopsies would be taken in the stomach for histological assessment of AG and IM
Sponsors
Chinese University of Hong Kong
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
Two groups of patients would be recruited in this case control study. 1. Gastric neoplasia group Patients with newly diagnosed or history of cancer of stomach or gastric high grade dysplasia. 2. Control group Patients with no prior history of gastric dysplasia or cancer Inclusion criteria: 1. Age 40 or above 2. Undergo elective upper gastrointestinal endoscopy
Exclusion criteria
1. Patients with history of gastrectomy 2. Patients with severe thrombocytopenia (Platelet count \<50) or coagulopathy (INR \> 1.5 or on anticoagulation) 3. Contraindication to upper gastrointestinal endoscopy 4. Allergy towards sedative agents (Midazolam / Diazepam) or local anaesthetic spray (Lignocaine) 5. Patients who cannot give informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Endoscopic grading of atrophic gastritis (Kimura Takemoto Classification) | Cross sectional study, day 0 | Endoscopic description of severity of gastric atrophy |
| Endoscopic grading of intestinal metaplasia (EGGIM) | Cross sectional study, day 0 | Endoscopic mapping of degree of intestinal metaplasia |
| Kyoto classification of gastritis | Cross sectional study, day 0 | Descriptive findings of gastritis |
| Operative links on gastritis assessment (OLGA) | Cross sectional study, day 0 | Biopsy based risk stratification panel based on severity of atrophic gastritis |
| Operative links on gastric intestinal metaplasia (OLGIM) | Cross sectional study, day 0 | Biopsy based risk stratification panel based on severity of intestinal metaplasia |
Countries
Hong Kong, Japan, Singapore, Thailand
Contacts
Primary ContactHon Chi Yip, FRCSEd(Gen)
Outcome results
None listed